Vericel Corporation (VCEL)
| Market Cap | 2.50B |
| Revenue (ttm) | 124.18M |
| Net Income (ttm) | 2.86M |
| Shares Out | 45.22M |
| EPS (ttm) | 0.06 |
| PE Ratio | 891.00 |
| Forward PE | 312.50 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 20 |
| Last Price | $53.46 |
| Previous Close | $54.77 |
| Change ($) | -1.31 |
| Change (%) | -2.39% |
| Day's Open | 54.75 |
| Day's Range | 51.26 - 55.21 |
| Day's Volume | 637,188 |
| 52-Week Range | 12.23 - 60.49 |
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...
The company will be a component of a well-known small-cap stock index.
NEW YORK, March 17, 2021 /PRNewswire/ -- Vericel Corp. (NASD:VCEL) will replace QEP Resources Inc. (NYSE:QEP) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 22. S&P 5...
In the latest trading session, Vericel Corporation (VCEL) closed at $42.92, marking a -0.26% move from the previous day.
Vericel to Present at the Oppenheimer 31st Annual Healthcare Conference on Wednesday, March 17, 2021
CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Col...
Sometimes valuation metrics can be deceiving.
Vericel Corporation (VCEL) delivered earnings and revenue surprises of 19.05% and 0.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Vericel (NASDAQ:VCEL) rose 1.0% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 25.00% year over year to $0.25, which beat the estimat...
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
In the latest trading session, Vericel Corporation (VCEL) closed at $51.15, marking a -0.04% move from the previous day.
Vericel Corporation (VCEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is (VCEL) Outperforming Other Medical Stocks This Year?
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
CAMBRIDGE, Mass., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that its Board...
Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Bull of the Day: Vericel (VCEL)
CAMBRIDGE, Mass., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, announced the appointment of J...
Record Quarterly and Full-Year Total Revenues
CAMBRIDGE, Mass., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that UnitedHea...
Vericel is a high growth, disruptive biotechnology company with annual sales increasing at a 30% rate prior to the COVID-19 pandemic. The Company's tissue repair and restoration products are proprietary...
The company's earnings are expected to increase exponentially in 2021
CAMBRIDGE, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Cola...
Vericel is a low-risk, high-quality small biotech with high growth potential. The business is already profitable with 70% gross profit margin and no debt on the balance sheet.
Vericel Corporation (VCEL) CEO Nick Colangelo on Q3 2020 Results - Earnings Call Transcript
Total Net Revenues of $32.3 Million and Net Income of $3.6 Million
Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.
Bull of the Day: Vericel (VCEL)
CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations ...
Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following ...
Double-Digit Revenue, Implant and Biopsy Growth for MACI in the Quarter and Record Monthly Biopsies in September
CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst an...
CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted ...
CAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentatio...
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick C...
YAVNE, Israel and CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedic...
Vericel Corporation (VCEL) CEO Nick Colangelo on Q2 2020 Results - Earnings Call Transcript
Product Revenues of $20.0 Million Reported for the Second Quarter
CAMBRIDGE, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the followin...
Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.
Second Quarter Net Product Revenues Expected to be Approximately $20 Million Second Quarter Net Product Revenues Expected to be Approximately $20 Million
CAMBRIDGE, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration ...
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Vericel's (VCEL) CEO Nick Colangelo on Q1 2020 Results - Earnings Call Transcript
Shares of Vericel (NASDAQ:VCEL) rose 2.2% after the company reported Q1 results. Quarterly Results Earnings per share fell 42.86% year over year to ($0.10), which missed the estimate of ($0.08).
Vericel Corporation: A Must-Have Biotech Post-COVID-19 Sell-Off - Behind The Idea
Vericel Is Substantially Undervalued Given Strong Balance Sheet, Profitability And Competitive Advantages
Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.
Vericel Corp (VCEL) CEO Dominick Colangelo on Q4 2019 Results - Earnings Call Transcript
About VCEL
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-de... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 1997 |
| CEO Dominick Colangelo | Employees 273 |
| Stock Exchange NASDAQ | Ticker Symbol VCEL |
Analyst Forecasts
According to 8 analysts, the average rating for Vericel stock is "Strong Buy." The 12-month stock price forecast is 61.21, which is an increase of 14.50% from the latest price.